Standard Treatment Remains the Recommended Approach for Patients with Bone Sarcoma Who Underwent Unplanned Surgery: Report from the Japanese Musculoskeletal Oncology Group

Background: The results of operations are not planned for bone sarcomas has not often discussed. However, it is important to recognize patterns, treatment, and clinical outcome of the operation was not planned for patients with bone sarcomas. The aim of this multicenter study to characterize the clinical outcome of patients with bone sarcoma who undergo planned operations.

Patients and methods: Data from 43 patients with bone sarcoma who undergo planned operations between 2006 and 2017 was obtained from 23 hospitals in Japan. These included 18 cases of osteosarcoma, Ewing sarcoma of 9, 8 of chondrosarcoma, and 6 undifferentiated pleomorphic sarcoma. The study involved 28 men and 15 women, with an average age of 46 years. The duration of the average follow-up was 59 months.

Results: The main primary tumor sites are the femur (n = 19), spine (n = 6), pelvis (n = 5), the tibia (n = 3), and humerus (n = 3). Diagnosis principal is benign bone tumors (n = 24), trauma (n = 7), bone metastases (n = 5), osteomyelitis (n = 4), degeneration (n = 2), and unknown (n = 1). As unplanned surgery, curettage, with or without bone graft, performed in 26 patients; Internal fixation is done at 7; spine surgery at 5; arthroplasty in 4; and arthroscopy in one.

Thirty-eight patients received standard treatments extra. Thirty-four patients underwent surgical resection of the tumor, including amputation (n = 10), and the remaining 4 receive radiotherapy or carbon ion radiotherapy for the treatment of additional standards. Level 5-year disease-specific survival (DSS) in patients with osteosarcoma, Ewing sarcoma, and chondrosarcoma was 65.5%, 58.3% and 72.9%, respectively. Twelve patients (27.9%) developed local recurrence (LR); among a total of 43 patients studied, the level of 5-year DSS was significantly worse for those who develop LR compared with those who did not (p = 0.03). 5-year DSS levels in patients with and without LR was 44% and 73.8%, respectively.

Conclusions: We recommend that patients undergoing surgery underwent unplanned given standard treatment, including the option to amputation because here, LR proved to be a risk factor for decreased DSS.

The Pathogenesis and Prevention Port-Site Metastasis in Gynecologic Oncology

Port-site metastases (PSM) is a specific and challenging complications of laparoscopic gynecologic oncology procedures. Research has shown that PSM is associated with morbidity and poor results. The exact pathogenesis of PSM in gynecological patients is not clear. Some precautions of PSM has been discussed in the relevant literature, and novel approaches to prevent this complication rarely keep up. In this review, we summarize the potential mechanisms of PSM and discuss the controversy and benefits of measures proposed prevention of PSM in gynecologic oncology.

We conducted a literature search using Medline database to identify studies of the pathogenesis and prevention of laparoscopic PSM. The hypothesis of the pathogenesis PSM at the center of the body’s immune response, pneumoperitoneum, contamination of wounds and surgical methods. convincing evidence of effective prevention of PSM after laparoscopic surgery is less. traditional preventive measures such as irrigation and tumor manipulation must be taken individually.

CO2 insufflation Hyperthermic and humidified CO2 leads to better outcomes in patients with malignant tumors who underwent laparoscopic procedures with the CO2 pneumoperitoneum than normal. Port-resection site showed no advantage in survival and outcome in the event of more injuries. PSM prevention plays an important part in the overall care of patients with gynecological malignancies who underwent laparoscopic procedures.

 Standard Treatment Remains the Recommended Approach for Patients with Bone Sarcoma Who Underwent Unplanned Surgery: Report from the Japanese Musculoskeletal Oncology Group
Standard Treatment Remains the Recommended Approach for Patients with Bone Sarcoma Who Underwent Unplanned Surgery: Report from the Japanese Musculoskeletal Oncology Group

End of the decision on the limitation of treatment in patients with cancer: an empirical analysis of the end-of-life practice of hematology and oncology unit at a university hospital in Germany

Background: The decision to limit treatment (DLTs) were essential to protect patients from overtreatment but it is one of the most ethically challenging situations in the practice of oncology. Ethics Policy Planning in Advance Care and Treatment study Limiting (EPAL), we examined how often DLT preceded the death of the patient and how early they were determined before (T1) and after (T2) the implementation of ethics policies intrainstitutional in DLT.

Methods: This prospective quantitative recruited 1,134 patients with hematology / oncology neoplasia within a period of 2 × 6 months at the Hospital of the University of Munich, Germany. Information on admission, discharge, diagnosis, age, DLT, date and place of death, and the time span between the initial determination of the DLT and the death of a patient are recorded using a standard form.

Results: Overall, 21% (n = 236) of the 1,134 patients, DLT was made. After the implementation of the policy, the proportion of reduction (26% T1 / T2 16%). However, the decision was more comprehensive, including more frequent combinations of ‘Do Not Resuscitate’ and ‘no intensive care unit’ (44% T1 / T2 64%). The median time between the determination of DLT and the patient’s death is equally short with 6 days in regular wards (each T1 / T2) and 10.5 / 9 (T1 / T2) days in the palliative care unit. For patients with solid tumors, DLTs made earlier in both routine and palliative care units than the deceased with hematologic neoplasia.

VEGFR-1/FLT-1 antibody

CAF50629-100ug 100ug
EUR 312

Recombinant Human FLT-1/VEGFR-1 Protein

RP01137 50μg
EUR 308.75

VEGFR-KDR/Flk-1 Antagonist Peptide

H-5896.0001 1.0mg
EUR 691.2
Description: Sum Formula: C77H99N23O18S; CAS# [492444-99-2] net

VEGFR-KDR/Flk-1 Antagonist Peptide

H-5896.0005 5.0mg
EUR 2648.4
Description: Sum Formula: C77H99N23O18S; CAS# [492444-99-2] net

Biotinylated Recombinant Human FLT-1/VEGFR-1 Protein

RP02100 500μg
EUR 2843.75

Mouse FLK-1/VEGFR-2 control/blocking peptide # 1

FLK11-P 100 ug
EUR 196.8

Rabbit Anti-human FLT-1/VEGFR-1 IgG #1, aff pure

FLT11-A 100 ul
EUR 578.4

Mouse Monoclonal Anti-human FLT-1/VEGFR-1 IgG, aff pure

FLT12-M 100 ug
EUR 578.4

Mouse Monoclonal Anti-human FLT-1/VEGFR-1 IgG, aff pure

FLT14-M 100 ug
EUR 578.4

VEGF receptor Flt-1 (F56), Peptide Aptamer, unlabeled

AP-334-U 5 mg Ask for price

Rabbit Anti-Mouse FLT-1/VEGFR-1 (279-299aa) IgG, aff pure

FLT15-A 100 ul
EUR 578.4

VEGF receptor Flt-1 (F56), Peptide Aptamer, Biotinylated

AP-334-B 1 mg Ask for price

VEGF receptor Flt-1 (F56), Peptide Aptamer, FITC labelled

AP-334-F 1 mg Ask for price

Rabbit Anti-Mouse FLT-4/VEGFR-3 IgG #1, aff pure

FLT41-A 100 ug
EUR 578.4

VEGF receptor KDR and Flt-1 (v107), Peptide Aptamer, unlabeled

AP-335-U 5 mg Ask for price

VEGF receptor KDR and Flt-1 (v107), Peptide Aptamer, Biotinylated

AP-335-B 1 mg Ask for price

VEGF receptor KDR and Flt-1 (v107), Peptide Aptamer, FITC labelled

AP-335-F 1 mg Ask for price

VEGFR-1/Flt1/ Rat VEGFR- 1/ Flt1 ELISA Kit

ELA-E0147r 96 Tests
EUR 1063.2

Human VEGFR-1/Flt1 ELISA Kit

EHV0045 96Tests
EUR 625.2

Human VEGFR1/Flt-1 ELISA KIT

E42EH-249 96T/48T Ask for price

Rabbit Anti-Human FLT-4/VEGFR-3 IgG #2, aff pure

FLT42-A 100 ug
EUR 578.4

Recombinant human VEGFR1/Flt-1 Protein

RP01188 5 μg
EUR 163.2

Anti-VEGFR-1/FLT-1 antibody

PAab09393 100 ug
EUR 426

VEGFR1 / Flt-1(FLT1/658) Antibody

BNCA0658-250 250uL
EUR 459.6
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/658), APC conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/659) Antibody

BNCA0659-250 250uL
EUR 459.6
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/659), APC conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/658) Antibody

BNC800658-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/658), CF680 conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/658) Antibody

BNC800658-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/658), CF680 conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/659) Antibody

BNC800659-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/659), CF680 conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/659) Antibody

BNC800659-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/659), CF680 conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/658) Antibody

BNC810658-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/658), CF680R conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/658) Antibody

BNC810658-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/658), CF680R conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/659) Antibody

BNC810659-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/659), CF680R conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/659) Antibody

BNC810659-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/659), CF680R conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/658) Antibody

BNC940658-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/658), CF594 conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/658) Antibody

BNC940658-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/658), CF594 conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/659) Antibody

BNC940659-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/659), CF594 conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/659) Antibody

BNC940659-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/659), CF594 conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/658) Antibody

BNC700658-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/658), CF770 conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/658) Antibody

BNC700658-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/658), CF770 conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/659) Antibody

BNC700659-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/659), CF770 conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/659) Antibody

BNC700659-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/659), CF770 conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/658) Antibody

BNC880658-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/658), CF488A conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/658) Antibody

BNC880658-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/658), CF488A conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/659) Antibody

BNC880659-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/659), CF488A conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/659) Antibody

BNC880659-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/659), CF488A conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/658) Antibody

BNC040658-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/658), CF405S conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/658) Antibody

BNC040658-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/658), CF405S conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/659) Antibody

BNC040659-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/659), CF405S conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/659) Antibody

BNC040659-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/659), CF405S conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/658) Antibody

BNC400658-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/658), CF640R conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/658) Antibody

BNC400658-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/658), CF640R conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/659) Antibody

BNC400659-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/659), CF640R conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/659) Antibody

BNC400659-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/659), CF640R conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/658) Antibody

BNC050658-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/658), CF405M conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/658) Antibody

BNC050658-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/658), CF405M conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/659) Antibody

BNC050659-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/659), CF405M conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/659) Antibody

BNC050659-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/659), CF405M conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/658) Antibody

BNCB0658-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/658), Biotin conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/658) Antibody

BNCB0658-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/658), Biotin conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/659) Antibody

BNCB0659-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/659), Biotin conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/659) Antibody

BNCB0659-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/659), Biotin conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/658) Antibody

BNCAP0658-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/658), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/658) Antibody

BNCAP0658-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/658), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/659) Antibody

BNCAP0659-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/659), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/659) Antibody

BNCAP0659-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/659), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/658) Antibody

BNCR0658-250 250uL
EUR 459.6
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/658), RPE conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/659) Antibody

BNCR0659-250 250uL
EUR 459.6
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/659), RPE conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/658) Antibody

BNCP0658-250 250uL
EUR 459.6
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/658), PerCP conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/659) Antibody

BNCP0659-250 250uL
EUR 459.6
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/659), PerCP conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/658) Antibody

BNUM0658-50 50uL
EUR 474
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/658), 1mg/mL

VEGFR1 / Flt-1(FLT1/659) Antibody

BNUM0659-50 50uL
EUR 474
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/659), 1mg/mL

VEGFR1 / Flt-1(FLT1/658) Antibody

BNCH0658-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/658), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/658) Antibody

BNCH0658-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/658), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/659) Antibody

BNCH0659-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/659), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/659) Antibody

BNCH0659-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/659), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/658) Antibody

BNUB0658-100 100uL
EUR 250.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/658), Concentration: 0.2mg/mL

VEGFR1 / Flt-1(FLT1/658) Antibody

BNUB0658-500 500uL
EUR 549.6
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/658), Concentration: 0.2mg/mL

VEGFR1 / Flt-1(FLT1/659) Antibody

BNUB0659-100 100uL
EUR 250.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/659), Concentration: 0.2mg/mL

VEGFR1 / Flt-1(FLT1/659) Antibody

BNUB0659-500 500uL
EUR 549.6
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/659), Concentration: 0.2mg/mL

VEGFR1 / Flt-1(FLT1/658) Antibody

BNC550658-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/658), CF555 conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/658) Antibody

BNC550658-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/658), CF555 conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/659) Antibody

BNC550659-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/659), CF555 conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/659) Antibody

BNC550659-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/659), CF555 conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/658) Antibody

BNC610658-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/658), CF660R conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/658) Antibody

BNC610658-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/658), CF660R conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/659) Antibody

BNC610659-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/659), CF660R conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/659) Antibody

BNC610659-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/659), CF660R conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/658) Antibody

BNC680658-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/658), CF568 conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/658) Antibody

BNC680658-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/658), CF568 conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/659) Antibody

BNC680659-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/659), CF568 conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/659) Antibody

BNC680659-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/659), CF568 conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/658) Antibody

BNC470658-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/658), CF647 conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/658) Antibody

BNC470658-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/658), CF647 conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/659) Antibody

BNC470659-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/659), CF647 conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/659) Antibody

BNC470659-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/659), CF647 conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/658) Antibody

BNC430658-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/658), CF543 conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/658) Antibody

BNC430658-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/658), CF543 conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/659) Antibody

BNC430659-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/659), CF543 conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/659) Antibody

BNC430659-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/659), CF543 conjugate, Concentration: 0.1mg/mL

Recombinant human VEGFR1/Flt-1 Protein, His Tag

E40KMP1308 20ug
EUR 495

VEGFR-1

E8RT1651 100ul
EUR 275
Description: Available in various conjugation types.

FLT-1/VEGFR1 Antibody (IHC Gold)

E36PA577 100ul
EUR 225
Description: Available in various conjugation types.

VEGFR-1 Antibody

48347-100ul 100ul
EUR 399.6

VEGFR-1 Antibody

48347-50ul 50ul
EUR 286.8

Rat VEGFR-1/Flt1 ELISA Kit

ERV0045 96Tests
EUR 625.2

Recombinant Human VEGFR1/FLT-1 Protein, Avi His Tag

E40KMP2138 20ug
EUR 495

Goat VEGFR-1/Flt1 ELISA Kit

EGTV0045 96Tests
EUR 625.2

Mouse VEGFR-1/Flt1 ELISA Kit

EMV0045 96Tests
EUR 625.2

VEGFR1 Peptide (OVA)

20-abx165607
  • EUR 693.60
  • EUR 309.60
  • EUR 2064.00
  • EUR 828.00
  • EUR 510.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Rabbit VEGFR-1/Flt1 ELISA Kit

ERTV0045 96Tests
EUR 625.2

Bovine VEGFR-1/Flt1 ELISA Kit

EBV0045 96Tests
EUR 625.2

Canine VEGFR-1/Flt1 ELISA Kit

ECV0045 96Tests
EUR 625.2

Porcine VEGFR-1/Flt1 ELISA Kit

EPV0045 96Tests
EUR 625.2

Anserini VEGFR-1/Flt1 ELISA Kit

EAV0045 96Tests
EUR 625.2

Mouse VEGFR1/Flt-1 ELISA KIT

E42EM-191 96T/48T Ask for price

Mouse Anti-Human Flt-1/VEGFR1 monoclonal antibody, clone JID688

CABT-L2814-100uL500uL 100 uL, 500 uL
EUR 602.4

VEGFR1 Blocking Peptide

AF7748-BP 1mg
EUR 234

VEGFR3 Blocking Peptide

AF4201-BP 1mg
EUR 234

VEGFR1 Blocking Peptide

AF6204-BP 1mg
EUR 234

VEGFR2 Blocking Peptide

AF6279-BP 1mg
EUR 234

VEGFR2 Blocking Peptide

AF6281-BP 1mg
EUR 234

VEGFR3 Blocking Peptide

DF2689-BP 1mg
EUR 234

VEGFR1 Blocking Peptide

20-abx161622
  • EUR 326.40
  • EUR 493.20
  • 1 mg
  • 5 mg

VEGFR1 Blocking Peptide

20-abx161858
  • EUR 326.40
  • EUR 493.20
  • 1 mg
  • 5 mg

VEGFR2 Blocking Peptide

20-abx161912
  • EUR 326.40
  • EUR 493.20
  • 1 mg
  • 5 mg

VEGFR2 Blocking Peptide

20-abx161913
  • EUR 326.40
  • EUR 493.20
  • 1 mg
  • 5 mg

VEGFR2 Blocking Peptide

20-abx161915
  • EUR 326.40
  • EUR 493.20
  • 1 mg
  • 5 mg

Human Vascuar endothelial cell growth factor receptor 3, VEGFR-3/Flt-4 ELISA Kit

CSB-E04765h-24T 1 plate of 24 wells
EUR 198
Description: Quantitative sandwich ELISA kit for measuring Human Vascuar endothelial cell growth factor receptor 3, VEGFR-3/Flt-4 in samples from serum, plasma, tissue homogenates. A new trial version of the kit, which allows you to test the kit in your application at a reasonable price.

Human Vascuar endothelial cell growth factor receptor 3, VEGFR-3/Flt-4 ELISA Kit

1-CSB-E04765h
  • EUR 843.60
  • EUR 5811.60
  • EUR 3084.00
  • 1 plate of 96 wells
  • 10 plates of 96 wells each
  • 5 plates of 96 wells each
Description: Quantitative sandwich ELISA kit for measuring Human Vascuar endothelial cell growth factor receptor 3, VEGFR-3/Flt-4 in samples from serum, plasma, tissue homogenates. Now available in a cost efficient pack of 5 plates of 96 wells each, conveniently packed along with the other reagents in 5 separate kits.

Human Vascuar endothelial cell growth factor receptor 3,VEGFR-3/Flt-4 ELISA Kit

EKC40132-48T 48T
EUR 474.04

Human Vascuar endothelial cell growth factor receptor 3,VEGFR-3/Flt-4 ELISA Kit

EKC40132-5x96T 5x96T
EUR 3216.7

Human Vascuar endothelial cell growth factor receptor 3,VEGFR-3/Flt-4 ELISA Kit

EKC40132-96T 96T
EUR 677.2

Human Vascuar endothelial cell growth factor receptor 3 (VEGFR-3/Flt-4) ELISA Kit

RK12064 96T
EUR 280

Human Vascuoar endothelial cell growth factor receptor 3,VEGFR-3/Flt-4 ELISA Kit

201-12-0216 96 tests
EUR 528
Description: A quantitative ELISA kit for measuring Human in samples from biological fluids.

Human Vascuoar endothelial cell growth factor receptor 3(VEGFR-3/Flt-4)ELISA Kit

GA-E0232HM-48T 48T
EUR 346.8

Human Vascuoar endothelial cell growth factor receptor 3(VEGFR-3/Flt-4)ELISA Kit

GA-E0232HM-96T 96T
EUR 559.2

Human Vascuoar endothelial cell growth factor receptor 3(VEGFR-3/Flt-4)ELISA Kit

QY-E00703 96T
EUR 433.2

Human Vascuoar endothelial cell growth factor receptor 3,VEGFR-3/Flt-4 ELISA Kit

YLA1379HU-48T 48T
EUR 435

Human Vascuoar endothelial cell growth factor receptor 3,VEGFR-3/Flt-4 ELISA Kit

YLA1379HU-96T 96T
EUR 562.5

Guinea Pig VEGFR-1/Flt1 ELISA Kit

EGV0045 96Tests
EUR 625.2

Biotinylated Recombinant Human VEGFR1/FLT-1 Protein, Avi His Tag

E40KMP2104 20ug
EUR 495

VEGFR2 (pY951) Blocking Peptide

20-abx161914
  • EUR 376.80
  • EUR 610.80
  • 1 mg
  • 5 mg

ELISA kit for Human VEGFR3/Flt-4

EK5791 96 tests
EUR 663.6
Description: Enzyme-linked immunosorbent assay kit for quantification of Human VEGFR3/Flt-4 in samples from serum, plasma, tissue homogenates and other biological fluids.

VEGFR1 (pY1213) Blocking Peptide

20-abx062629
  • EUR 376.80
  • EUR 610.80
  • 1 mg
  • 5 mg

VEGFR2 (pY1214) Blocking Peptide

20-abx061614
  • EUR 360.00
  • EUR 594.00
  • 1 mg
  • 5 mg

VEGFR2 (pY1175) Blocking Peptide

20-abx162540
  • EUR 376.80
  • EUR 610.80
  • 1 mg
  • 5 mg

Human Vascuoar endothelial cell growth factor receptor 1,VEGFR-1/Flt1 ELISA kit

201-12-0249 96 tests
EUR 528
Description: A quantitative ELISA kit for measuring Human in samples from biological fluids.

Human vascular endothelial cell growth factor receptor 1 (VEGFR-1/Flt1) ELISA kit

CSB-E11885h-24T 1 plate of 24 wells
EUR 198
Description: Quantitativesandwich ELISA kit for measuring Human vascular endothelial cell growth factor receptor 1 (VEGFR-1/Flt1) in samples from serum, plasma, tissue homogenates. A new trial version of the kit, which allows you to test the kit in your application at a reasonable price.

Human vascular endothelial cell growth factor receptor 1 (VEGFR-1/Flt1) ELISA kit

1-CSB-E11885h
  • EUR 813.60
  • EUR 5572.80
  • EUR 2960.40
  • 1 plate of 96 wells
  • 10 plates of 96 wells each
  • 5 plates of 96 wells each
Description: Quantitativesandwich ELISA kit for measuring Human vascular endothelial cell growth factor receptor 1 (VEGFR-1/Flt1) in samples from serum, plasma, tissue homogenates. Now available in a cost efficient pack of 5 plates of 96 wells each, conveniently packed along with the other reagents in 5 separate kits.

Human Vascuoar endothelial cell growth factor receptor 1(VEGFR-1/Flt1)ELISA Kit

GA-E0265HM-48T 48T
EUR 346.8

Human Vascuoar endothelial cell growth factor receptor 1(VEGFR-1/Flt1)ELISA Kit

GA-E0265HM-96T 96T
EUR 559.2

Human Vascuoar endothelial cell growth factor receptor 1(VEGFR-1/Flt1)ELISA Kit

QY-E00705 96T
EUR 433.2

Human vascular endothelial cell growth factor receptor 1 (VEGFR-1/Flt1) ELISA kit

EKC40822-48T 48T
EUR 511.7

Human vascular endothelial cell growth factor receptor 1 (VEGFR-1/Flt1) ELISA kit

EKC40822-5x96T 5x96T
EUR 3472.25

Human vascular endothelial cell growth factor receptor 1 (VEGFR-1/Flt1) ELISA kit

EKC40822-96T 96T
EUR 731

Human Vascuoar endothelial cell growth factor receptor 1,VEGFR-1/Flt1 ELISA kit

YLA1567HU-48T 48T
EUR 435

Human Vascuoar endothelial cell growth factor receptor 1,VEGFR-1/Flt1 ELISA kit

YLA1567HU-96T 96T
EUR 562.5

Human Vascular endothelial cell growth factor receptor 1 (VEGFR-1/Flt1) ELISA Kit

RK10114 96T
EUR 280

Human VEGF R1/Flt-1 ELISA Kit

E28L0417 96T
EUR 666.67

Human Antigen Peptide Transporter 1 (TAP1) Peptide

20-abx650298
  • EUR 777.60
  • EUR 326.40
  • EUR 2397.60
  • EUR 927.60
  • EUR 560.40
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Mouse Vascuoar endothelial cell growth factor receptor,VEGFR-3/Flt-4 ELISA Kit

SL0562Mo -
EUR 528

Rabbit Anti-Mouse FLK-1/VEGFR-2 IgG #1, aff pure

FLK11-A 100 ug
EUR 578.4

Mouse Vascular endothelial cell growth factor receptor 3 (VEGFR-3/Flt-4) ELISA kit

CSB-E04766m-24T 1 plate of 24 wells
EUR 198
Description: Quantitativesandwich ELISA kit for measuring Mouse Vascular endothelial cell growth factor receptor 3 (VEGFR-3/Flt-4) in samples from serum, plasma, tissue homogenates. A new trial version of the kit, which allows you to test the kit in your application at a reasonable price.

Mouse Vascular endothelial cell growth factor receptor 3 (VEGFR-3/Flt-4) ELISA kit

1-CSB-E04766m
  • EUR 843.60
  • EUR 5811.60
  • EUR 3084.00
  • 1 plate of 96 wells
  • 10 plates of 96 wells each
  • 5 plates of 96 wells each
Description: Quantitativesandwich ELISA kit for measuring Mouse Vascular endothelial cell growth factor receptor 3 (VEGFR-3/Flt-4) in samples from serum, plasma, tissue homogenates. Now available in a cost efficient pack of 5 plates of 96 wells each, conveniently packed along with the other reagents in 5 separate kits.

Mouse Vascuoar endothelial cell growth factor receptor 3(VEGFR-3/Flt-4)ELISA Kit

GA-E0679MS-48T 48T
EUR 403.2

Mouse Vascuoar endothelial cell growth factor receptor 3(VEGFR-3/Flt-4)ELISA Kit

GA-E0679MS-96T 96T
EUR 640.8

Mouse Vascular endothelial cell growth factor receptor 3 (VEGFR-3/Flt-4) ELISA kit

EKC42223-48T 48T
EUR 474.04

Mouse Vascular endothelial cell growth factor receptor 3 (VEGFR-3/Flt-4) ELISA kit

EKC42223-5x96T 5x96T
EUR 3216.7

Mouse Vascular endothelial cell growth factor receptor 3 (VEGFR-3/Flt-4) ELISA kit

EKC42223-96T 96T
EUR 677.2

Mouse Vascuoar endothelial cell growth factor receptor 3(VEGFR-3/Flt-4)ELISA Kit

YLA0289MO-48T 48T
EUR 465

Mouse Vascuoar endothelial cell growth factor receptor 3(VEGFR-3/Flt-4)ELISA Kit

YLA0289MO-96T 96T
EUR 600

Recombinant Human VEGF Receptor 1/VEGF R1/FLT-1 (C-Fc)

CJ93-10ug 10ug
EUR 169.2
Description: Lyophilized from a 0.2 μm filtered solution of PBS,pH7.4.

Recombinant Human VEGF Receptor 1/VEGF R1/FLT-1 (C-Fc)

CJ93-1mg 1mg
EUR 2008.8
Description: Lyophilized from a 0.2 μm filtered solution of PBS,pH7.4.

Recombinant Human VEGF Receptor 1/VEGF R1/FLT-1 (C-Fc)

CJ93-500ug 500ug
EUR 1338
Description: Lyophilized from a 0.2 μm filtered solution of PBS,pH7.4.

Recombinant Human VEGF Receptor 1/VEGF R1/FLT-1 (C-Fc)

CJ93-50ug 50ug
EUR 363.6
Description: Lyophilized from a 0.2 μm filtered solution of PBS,pH7.4.

Tau Peptide (1-16) (human)

H-8004.0500 0.5mg
EUR 135.6
Description: Sum Formula: C77H120N20O28S3; CAS# [2022956-53-0] net

Tau Peptide (1-16) (human)

H-8004.1000 1.0mg
EUR 205.2
Description: Sum Formula: C77H120N20O28S3; CAS# [2022956-53-0] net

Anti-Inflammatory Peptide 1

20-abx266089
  • EUR 493.20
  • EUR 794.40
  • EUR 376.80
  • 10 mg
  • 25 mg
  • 5 mg

Conclusions: Our results show that the ethics policy in DLT be sensitive to the limitations of treatment in terms of frequency and extension but did not have a significant impact on the time DLT. Since patients with hematological malignancies tend to undergo intensive therapy more frequently during their final days than patients with solid tumors, particular attention should be given to this group. To support the timely discussion, we suggest that the concept of advance care planning.

Related Posts

Leave a Reply

Your email address will not be published.